Home › Research › Getting a diagnosis
A critical evaluation of the Braak staging scheme for Parkinson's disease
Burke RE, Dauer WT, Vonsattel JP.. Annals of neurology, 2008-11-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Braak and colleagues have proposed that, within the central nervous system, Parkinson's disease (PD) begins as a synucleinopathy in nondopaminergic structures of the lower brainstem or in the olfactory bulb. The brainstem synucleinopathy is postulated to progress rostrally to affect the substantia nigra and cause parkinsonism at a later stage of the disease. In the context of a diagnosis of PD, made from current clinical criteria, the pattern of lower brainstem involvement accompanying mesencephalic synucleinopathy is often observed. However, outside of that context, the patterns of synucleinopathy that Braak described are often not observed, particularly in dementia with Lewy bodies and when synucleinopathy occurs in the absence of neurological manifestations. The concept that lower brainstem synucleinopathy represents "early PD" rests on the supposition that it has a substantial likelihood of progressing within the human lifetime to involve the mesencephalon, and thereby cause the substantia nigra pathology and clinical parkinsonism that have heretofore defined the disease. However, the predictive validity of this concept is doubtful, based on numerous observations made in populations of aged individuals who, despite the absence of neurological signs, have brain synucleinopathy ranging up to Braak stages 4 to 6 at postmortem. Furthermore, there is no relation between Braak stage and the clinical severity of PD. We conclude that the relation between patterns of abnormal synuclein immunostaining in the human brain and the disease entity now recognized as PD remains to be determined.
What this study adds
Evidence grade: Low
Braak's scheme holds that Parkinson's disease begins as synuclein pathology in the lower brainstem or olfactory bulb and spreads upward. This 2008 critique argues that the scheme's predictive value is doubtful: many older people with no neurological signs have Braak stage 4–6 synuclein pathology at autopsy, and Braak stage shows no relation to how severe a patient's Parkinson's is.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Burke, R. E., Dauer, W. T., & Vonsattel, J. P. (2008). A critical evaluation of the Braak staging scheme for Parkinson's disease. Annals of neurology. https://doi.org/10.1002/ana.21541
Vancouver
Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Annals of neurology. 2008. doi:10.1002/ana.21541. PMID: 19067353.
BibTeX
@article{burke2008-19067353,
author = {Burke, R. E. and Dauer, W. T. and Vonsattel, J. P.},
title = {{A critical evaluation of the Braak staging scheme for Parkinson's disease}},
journal = {Annals of neurology},
year = {2008},
doi = {10.1002/ana.21541},
pmid = {19067353},
url = {https://doi.org/10.1002/ana.21541}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- We conclude that the relation between patterns of abnormal synuclein immunostaining in the human brain and the disease entity now recognized as PD remains to be determined.
Why it matters
Braak's scheme holds that Parkinson's disease begins as synuclein pathology in the lower brainstem or olfactory bulb and spreads upward. This 2008 critique argues that the scheme's predictive value is doubtful: many older people with no neurological signs have Braak stage 4–6 synuclein pathology at autopsy, and Braak stage shows no relation to how severe a patient's Parkinson's is. The authors conclude that how these staining patterns relate to Parkinson's disease "remains to be determined". The paper is about Parkinson's pathology, not Alzheimer's disease.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Evidence strengthLow
How this study scored 49/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of neurology) |
| Journal's citation record | 3 / 4 | Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 378 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 18.9 citations a year over 20 year(s) since 2008 |
| Impact for its field and year | 4 / 6 | Cited 17.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 2 / 4 | Cited 42 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jean Paul Vonsattel: h-index 70 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Columbia University: institution h-index 1,824 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19067353) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Getting a diagnosis from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.